Interestingly, glucocorticoid treatment was found to have no effect on sputum MPO level in COPD patients, regardless of the route of administration and dosage, which further demonstrated that airway neutrophilic inflammation is not responsive to glucocorticoids [25]. This evidence concerns the gene MPO and chronic obstructive pulmonary disease.